
Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

Genmab and argenx combine antibody know-how
Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the...

Medigene licences CD40L-CD28 costimulatory switch receptor
Medigene has licences the global exclusive rights for CD40L-CD28 costimulatory switch receptor from the Helmholtz Centre Munich. Financial details...

Wacker AG expands biotech business through €100m acquisition
Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...

Roche’s meets endpoints in relapsing multiple sclerosis
In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...